Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.
Your search for apixaban returned 48 results
Asundexian is an investigational oral Factor XIa inhibitor.
Almost all the various treatment options for acute venous thromboembolism are equally safe and effective, according to a new study.
Adaptive design allows evaluation of various doses, types of blood thinners in outpatients, inpatients.
And antithrobotic medications linked to higher rate of hematuria-related events in older adults
Andexxa was granted accelerated approval by the FDA in May 2018.
Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin
Neurologists, internists and cardiologists differ markedly in their prescribing beliefs when it comes to the prevention of ischemic stroke due to atrial fibrillation, according to survey results.